Gene-editing therapies
The company reports research projects for β-thalassemia, PD1-knockout CAR-T and UCART.
Source: LinkedIn company description · Retrieved October 13, 2026
BRL Medicine develops human therapeutics through gene-editing-led innovation.
The company reports five technology platforms with independent intellectual property rights, covering gene editing, hematopoietic stem cells, CAR-T, universal cells and enhanced T cells. The company reports more than 100 patent achievements and initiated investigator-led clinical trials at hospitals in China.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
The company reports research projects for β-thalassemia, PD1-knockout CAR-T and UCART.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 2, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 14, 2026, September 15, 2026, September 16, 2026, September 18, 2026, September 19, 2026, October 7, 2026, October 8, 2026 and October 10, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.